Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma
NCT03199274Phase 2Completed
- Sponsor
- Thomas Jefferson University
- Start
- Jul 2017
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of perflutren protein type a in hepatocellular carcinoma (HCC), sponsored by Thomas Jefferson University. Started Jul 2017; status: completed.
02
Drugs
perflutren protein type a
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03199274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199274.